RT Journal Article
SR Electronic
T1 Deviations in Predicted COVID-19 cases in the US during early months of 2021 relate to rise in B.1.526 and its family of variants
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.12.06.21267388
DO 10.1101/2021.12.06.21267388
A1 Nandakishore, P.
A1 Liu, M.
A1 R., Prakash
A1 Gourneni, S.
A1 Sukumaran, R.
A1 Berman, J.M.
A1 Iyer, S.
A1 Glorioso, C.
YR 2021
UL http://medrxiv.org/content/early/2021/12/08/2021.12.06.21267388.abstract
AB Objective To investigate the abrogation of COVID-19 case declines from predicted rates in the US in relationship to viral variants and mutations.Design Epidemiological prediction and time series study of COVID-19 in the US by State.Setting Community testing and sequencing of COVID-19 in the US.Participants Time series US COVID-19 case data from the Johns Hopkins University CSSE database. Time series US Variant and Mutation data from the GISAID database.Main outcome measures Primary outcomes were statistical modeling of US state deviations from epidemiological predictions, percentage of COVID-19 variants, percentage of COVID-19 mutations, and reported SARS-CoV-2 infections.Results Deviations in epidemiological predictions of COVID-19 case declines in the North Eastern US in March 2021 were highly positively related to percentage of B.1.526 (Iota) lineage (p < 10e − 7) and B.1.526.2 (p < 10 − 8) and the T95I mutation (p < 10e − 9). They were related inversely to B.1.427 and B.1.429 (Epsilon) and there was a trend for association with B.1.1.7 (Alpha) lineage.Conclusion Deviations from accurate predictive models are useful for investigating potential immune escape of COVID-19 variants at the population level. The B.1.526 and B.1.526.2 lineages likely have a high potential for immune escape and should be designated as variants of concern. The T95I mutation which is present in the B.1.526, B.1.526.2, and B.1.617.2 (Delta) lineages in the US warrants further investigation as a mutation of concern.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study did not receive any funding.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors.